uploads/2018/08/Chart-06-1.jpg

These Products Saw Falling Sales in Pfizer’s Q2 2018

By

Updated

Products with falling sales

Pfizer’s (PFE) portfolio also includes a few products that are losing market share due to competition from other products in the market. These products include Enbrel (outside the United States and Canada), Sutent, Xalkori, BeneFix, Premarin Family, Medrol, Celebrex, Lyrica, and Viagra.

The chart above compares the products that reported revenue falls in Pfizer’s second quarter.

Article continues below advertisement

Negative growth products

The following products’ revenues were affected by lower sales in the quarter:

  • Xalkori reported revenue of $137 million in the second quarter, an 11% fall YoY (year-over-year) driven by a 34% fall in US sales to $42 million and partially offset by a 5% rise in international sales to $96 million.
  • Enbrel reported revenue of $551 million in the second quarter, an 11% fall YoY. Its revenue included sales from outside the US and Canadian markets.
  • BeneFIX reported revenue of $141 million in the second quarter, an 8% fall YoY driven by a 1% fall in international sales to $83 million and a 16% fall in US sales to $58 million.
  • Celebrex reported revenue of $161 million in the second quarter, a 9% fall YoY driven by a fall in US sales to $18 million and a 6% fall in international sales to $143 million.
  • Viagra reported revenue of $185 million in the second quarter, a 47% fall YoY driven by a 70% fall in US sales to $75 million and offset by an 8% rise in international sales to $109 million.

The iShares Core High Dividend ETF (HDV) holds 5.8% of its total investments in Pfizer, 6.8% in Johnson & Johnson (JNJ), 1.9% in Bristol-Myers Squibb (BMY), and 1.6% in Eli Lilly and Company (LLY).

Advertisement

More From Market Realist